Speaking today (Tuesday 31 October) at the White Rose Bioscience Forum in York, Adams encourages companies to consider both their strengths and weaknesses, and to be open to all potential collaborations to ensure a healthy product portfolio.
“My advice is: be flexible, think out the box; what you can offer as company? Think about what you’ve got, be it technology or know how, and think hard about how you can capitalise on it. The whole company can contribute to this – talk to the research group and ask what else could we do with this technology, or put with this technology, and who could we talk to that they have contacts with? You’ll be surprised how many potential opportunities are generated from this creative brainstorming.”
This advice is based on Antisoma’s own experience. The company does not have a discovery arm; most of what it does is licensed directly from academia or from other biotechs, so it has to be creative in forging the right alliances to create a thriving product pipeline.
“Preclinically our focus is biology and we have enormous expertise in this area,” says Adams. This strength is very attractive to companies whose expertise lies on the chemistry side who have products that need biology.”
Since most cancer therapies around today are derived from plants, Antisoma was very interested to hear from a company contact about a young Australian company, Ecobiotics. Its expertise lay in its knowledge of the different chemical properties of Queensland rainforest plants at various stages of the plants’ growth. Says Adams: “Ecobiotics researchers knew how to select and synthesise the chemicals from various rainforest plants, but lacked the biological expertise, cancer models and in vitro capability.”
Antisoma and Ecobiotics now have a fruitful collaboration underpinned by a simple and transparent agreement.
“No money was exchanged up front and there are no unnecessary legal complexities. They provide us with molecules that display anti-cancer properties, we test them, and all resulting data is shared. Whilst Ecobiotics owns the IP, Antisoma has the right to select up to two molecule classes each year for development. All other test results on other molecules are owned by Ecobiotics which is free to develop the molecule further or offer it to other parties. It’s a perfect solution – they have the chemistry and we have the biology.
"I liken our networking approach to creating a spider’s web down whose strands products can come, whether developed in house, through collaborations or licensed in. The more strands you have the more chance you have of getting products to feed into your pipeline,” he says.
Jo Kelly | alfa
How Strong Brands Translate into Money
15.11.2016 | Kühne Logistics University - Wissenschaftliche Hochschule für Logistik und Unternehmensführung
Demographic change depresses tax revenues
04.11.2016 | Fraunhofer-Institut für Angewandte Informationstechnik FIT
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
19.01.2017 | Earth Sciences
19.01.2017 | Life Sciences
19.01.2017 | Physics and Astronomy